2015
DOI: 10.1007/s12029-015-9739-7
|View full text |Cite
|
Sign up to set email alerts
|

Review of Neoadjuvant Chemotherapy Alone in Locally Advanced Rectal Cancer

Abstract: This review demonstrates that neoadjuvant chemotherapy could be affectively administered in LARC and could provide a good alternative to chemoradiotherapy in moderate-risk rectal cancers without compromising short- and long-term outcomes.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
14
0
2

Year Published

2016
2016
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 30 publications
(16 citation statements)
references
References 40 publications
0
14
0
2
Order By: Relevance
“…Although results in terms of overall and disease‐free survival may be impressive, the therapeutic decision should be taken carefully by a multidisciplinary team, balancing possible benefits and drawbacks. Interestingly, neoadjuvant chemotherapy was not described by JSCCR guidelines, even though its positive outcomes have been widely demonstrated.…”
Section: Discussionmentioning
confidence: 99%
“…Although results in terms of overall and disease‐free survival may be impressive, the therapeutic decision should be taken carefully by a multidisciplinary team, balancing possible benefits and drawbacks. Interestingly, neoadjuvant chemotherapy was not described by JSCCR guidelines, even though its positive outcomes have been widely demonstrated.…”
Section: Discussionmentioning
confidence: 99%
“…All of the mentioned strategies aimed at enhancing either the chemo- or the radiation part during concurrent chemoradiation and therefore allowed only moderate escalations due to concerns of toxicity. However, dose-intense combination chemotherapy regimens alone may result in considerable rates of downstaging and pCR rates as indicated by several studies [ 143 ]. Therefore, it seems reasonable to combine chemoradiation with sequential dose-intense combination chemotherapy in the neoadjuvant setting to improve pCR rates (known as TNT).…”
Section: Neoadjuvant Treatment Intensificationmentioning
confidence: 99%
“…28 Neoadjuvantno liječenje može započeti u obliku kemoterapije temeljene na oksaliplatini (FOLFOX, CAPEOX) ili kapecitabinu ili 5-FU/LV, praćeno prethodno opisanom kemoradioterapijom te zatim već opisanom kirurškom resekcijom. 29,30 Adjuvantna kemoradioterapija indicirana je bolesnicima s rakom rektuma T3-4, N1-2, a primjenjuje se na isti način kao i neoadjuvantna kemoradioterapija, nakon čega slijedi nastavak adjuvantne kemoterapije prema prije definiranim smjernicama adjuvantnog liječenja (IA). 28,[31][32][33][34] Perioperativno onkološko liječenje ne bi trebalo trajati više od 6 mjeseci.…”
Section: T4aunclassified